Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 add-on to tiotropium in COPD
2016-004450-15Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Verona Pharma. Primary endpoints: Peak FEV1 and AUC0-12h FEV1. Started Nov 2016; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-004450-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004450-15.